Drug Profile
Ezetimibe/rosuvastatin - Navipharm
Alternative Names: NVP-1205; Rosuvastatin/ezetimibe - NavipharmLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Navipharm
- Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 18 Mar 2019 Chemical structure information added
- 14 Mar 2019 No recent reports of development identified for preregistration for Dyslipidaemias in South Korea (PO)
- 12 Nov 2014 Navipharm Corporation plans a phase I trial in Healthy male volunteers in South Korea (NCT02289430)